Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial
Posted inCardiology Internal Medicine news

Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial

The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
Posted inCardiology Nephrology news

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline KDIGO kidney risk category, while maintaining a manageable safety profile.
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
Posted inCardiology Diabetes & Endocrinology news

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase inhibitor AT-001 showed consistent safety and efficacy across both sexes.
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
Posted inCardiology Internal Medicine news

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microvascular health and maintaining patient quality of life.
ACT-Based Parenting Interventions Significantly Reduce Caregiver Stress and Improve Child Outcomes in Autism Spectrum Disorder
Posted innews Pediatrics Psychiatry

ACT-Based Parenting Interventions Significantly Reduce Caregiver Stress and Improve Child Outcomes in Autism Spectrum Disorder

A randomized clinical trial demonstrates that an 8-week Acceptance and Commitment Therapy (ACT) program significantly reduces parental stress and improves psychological flexibility and parenting competence, while also yielding positive secondary benefits for children's emotional and behavioral health over a 6-month period.
Digital Storytelling Boosts Pediatric Influenza Vaccination Rates Despite Low Engagement: Insights from a Pilot Randomized Trial
Posted innews Pediatrics Public Health

Digital Storytelling Boosts Pediatric Influenza Vaccination Rates Despite Low Engagement: Insights from a Pilot Randomized Trial

A pilot randomized clinical trial reveals that text-based digital stories centered on community voices significantly improved influenza vaccination rates among children in Black communities, even though only 7% of caregivers viewed the narratives, highlighting a potential high-impact intervention for health equity.